

# Shaozhao Zhang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3858682/publications.pdf>

Version: 2024-02-01

25  
papers

145  
citations

1307594

7  
h-index

1372567

10  
g-index

31  
all docs

31  
docs citations

31  
times ranked

162  
citing authors

#	ARTICLE	IF	CITATIONS
1	Klotho attenuated Doxorubicin-induced cardiomyopathy by alleviating Dynamin-related protein 1 - mediated mitochondrial dysfunction. <i>Mechanisms of Ageing and Development</i> , 2021, 195, 111442.	4.6	16
2	Time in Target Range for Systolic Blood Pressure and Cardiovascular Outcomes in Patients With Heart Failure With Preserved Ejection Fraction. <i>Journal of the American Heart Association</i> , 2022, 11, e022765.	3.7	16
3	Serum magnesium and the prevalence of peripheral artery disease: The Atherosclerosis Risk in Communities (ARIC) study. <i>Atherosclerosis</i> , 2019, 282, 196-201.	0.8	14
4	Toward a panoramic perspective of the association between environmental factors and cardiovascular disease: An environment-wide association study from National Health and Nutrition Examination Survey 1999â€”2014. <i>Environment International</i> , 2018, 118, 146-153.	10.0	13
5	Assessment of Visit-to-Visit Blood Pressure Variability in Adults With Optimal Blood Pressure: A New Player in the Evaluation of Residual Cardiovascular Risk?. <i>Journal of the American Heart Association</i> , 2022, 11, e022716.	3.7	11
6	Effectiveness of blood pressure-lowering treatment by the levels of baseline Framingham risk score: A post hoc analysis of the Systolic Blood Pressure Intervention Trial (SPRINT). <i>Journal of Clinical Hypertension</i> , 2019, 21, 1813-1820.	2.0	10
7	Lipid management for coronary heart disease patients: an appraisal of updated international guidelines applying Appraisal of Guidelines for Research and Evaluation IIâ€”clinical practice guideline appraisal for lipid management in coronary heart disease. <i>Journal of Thoracic Disease</i> , 2019, 11, 3534-3546.	1.4	8
8	Intensive blood pressure treatment in coronary artery disease: implications from the Systolic Blood Pressure Intervention Trial (SPRINT). <i>Journal of Human Hypertension</i> , 2022, 36, 86-94.	2.2	8
9	Antiplatelet strategy in primary and secondary prevention of cardiovascular disease in patients with type 2 diabetes mellitus: A perspective from the guideline appraisal. <i>Journal of Diabetes Investigation</i> , 2021, 12, 99-108.	2.4	7
10	Visit-to-Visit Fasting Glucose Variability in Young Adulthood and Hippocampal Integrity and Volume at Midlife. <i>Diabetes Care</i> , 2019, 42, 2334-2337.	8.6	6
11	Long-Term Visit-to-Visit Mean Arterial Pressure Variability and the Risk of Heart Failure and All-Cause Mortality. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 665117.	2.4	5
12	Critical appraisal of guidelines for coronary artery disease on dual antiplatelet therapy: More consensus than controversies. <i>Clinical Cardiology</i> , 2019, 42, 1170-1180.	1.8	4
13	Short-chain fatty acids combined with intronic DNA methylation of HIF3A: Potential predictors for diabetic cardiomyopathy. <i>Clinical Nutrition</i> , 2021, 40, 3708-3717.	5.0	4
14	Urban index and lifestyle risk factors for cardiovascular diseases in China: A cross-sectional study. <i>Science Progress</i> , 2021, 104, 003685042110037.	1.9	4
15	An appraisal of clinical practice guidelines for the appropriate use of echocardiography for adult infective endocarditisâ€”the timing and mode of assessment (TTE or TEE). <i>BMC Infectious Diseases</i> , 2021, 21, 92.	2.9	4
16	Risk Stratification and Efficacy of Spironolactone in Patients with Heart Failure with Preserved Ejection Fraction: Secondary Analysis of the TOPCAT Randomized Clinical Trial. <i>Cardiovascular Drugs and Therapy</i> , 2021, , 1.	2.6	3
17	Behavioral Factors Mediating the Impact of Educational Attainment on Incident Heart Failureâ€”A Mediation Analysis. <i>Circulation Journal</i> , 2021, 85, 1545-1552.	1.6	3
18	Critical Appraisal of Guidelines for Antithrombotic Therapy in Atrial Fibrillation Post-Percutaneous Coronary Intervention. <i>Global Heart</i> , 2022, 17, 14.	2.3	3

#	ARTICLE	IF	CITATIONS
19	Association of Mid- to Late-Life Blood Pressure Patterns With Risk of Subsequent Coronary Heart Disease and Death. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 632514.	2.4	2
20	Six-Year Change in QT Interval Duration and Risk of Incident Heart Failure—A Secondary Analysis of the Atherosclerosis Risk in Communities Study. <i>Circulation Journal</i> , 2021, 85, 640-646.	1.6	1
21	Intensity of Glycemic Exposure in Early Adulthood and Target Organ Damage in Middle Age: The CARDIA Study. <i>Frontiers in Physiology</i> , 2021, 12, 614532.	2.8	1
22	Visit-to-Visit Fasting Glucose Variability in Young Adulthood and Cardiac Structure and Function at Midlife: The CARDIA Study. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 687054.	2.4	1
23	Impact of RAAS Blockers on Contrast-Induced Nephropathy in Patients With Renal Insufficiency: A Meta-Analysis. <i>Journal of Cardiovascular Pharmacology</i> , 2020, 76, 692-697.	1.9	1
24	Letter by Zhang et al Regarding Article, “Twenty Year Trends and Sex Differences in Young Adults Hospitalized With Acute Myocardial Infarction: The ARIC Community Surveillance Study”. <i>Circulation</i> , 2019, 140, e329-e330.	1.6	0
25	Appraisal of Guidelines for the Management of Blood Pressure in Patients with Diabetes Mellitus: The Consensuses, Controversies and Gaps. <i>Diabetes and Metabolism Journal</i> , 2021, 45, 753-764.	4.7	0